Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...

FDA to establish national standard and timeline for food industry to transition from petrochemical-based dyes to natural alternatives.

“Tegoprazan offers an exciting new treatment option for individuals suffering from GERD, helping to address the substantial unmet need of patients not well-controlled by conventional PPI therapy,” ...

Dr David Sugerman, a senior scientist at the CDC, said that the agency is "scraping to find the resources" to support states affected by the outbreaks.

The FDA issues alert regarding compounded topical finasteride; plant-based alkaloid shows improvements for smoking cessation; potential new treatment option for GERD; and the CDC’s Advisory Committee ...

Both the FDA and Novo Nordisk are advising patients and providers to check their supplies of Ozempic for counterfeit product.

HealthDay News — A single-dose baloxavir treatment can reduce influenza transmission from index patients to household contacts, according to a study published in the April 24 issue of the New England ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to BA-102 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder linked to autism.

Meanwhile, a new registry is being created to track those with autism, and that information will be part of the database.

After 3 initial monthly injections, current dosing intervals range from every 8 to 16 weeks in patients with wAMD and DME and every 8 to 12 weeks in patients with DR.

The DOJ has accused CHEST and other medical journals of scientific bias, demanding responses to a list of questions by May 2, 2025.